Ovarian Cancer Trial, Recruiting NCT03841981 Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT03841981
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The trial has five separate groups. People may be considered for one of the following groups:

Group I:

  • People with a body mass index (BMI) between 18.5 and 25.0
  • People who have a type of ovulation problem classified as "Group 1" by the World Health Organization
  • People with low or normal levels of certain reproductive hormones (FSH and LH) and low estrogen levels
  • People who do more than 5 hours per week of moderate to vigorous exercise and have low energy intake relative to their body composition
  • People who have had other causes of their ovulation problems ruled out
  • People who have signed an informed consent form

Group II:

  • People diagnosed with Polycystic Ovary Syndrome (PCOS) of a specific type (phenotype I, II, or III by NIH-2012 guidelines) that includes high levels of male hormones
  • People with a BMI between 18.5 and 40.0
  • People who have signed an informed consent form

Group III:

  • People diagnosed with a specific type of PCOS (phenotype IV by NIH-2012 guidelines)
  • People with a BMI between 18.5 and 40.0
  • People who have signed an informed consent form

Group IV:

  • People with a BMI between 18.5 and 25.0
  • People who have regular menstrual periods
  • People with normal reproductive hormone levels during the first part of their menstrual cycle
  • People who do more than 5 hours per week of moderate to vigorous exercise and eat enough to support their body composition
  • People who have signed an informed consent form

Group V:

  • People with no signs or symptoms of high male hormone levels
  • People who do no exercise or only light physical activity
  • People who have regular menstrual periods
  • People with a BMI between 18.5 and 40.0
  • People who have signed an informed consent form

Who may not be able to join:

  • People who have taken certain medications in the past 6 months that can affect ovulation, including steroids, antipsychotics, antidepressants, contraceptives, hormones, or opioids
  • People who are currently pregnant or breastfeeding, or who have been pregnant or breastfeeding in the past 6 months
  • People who have a uterine condition called Asherman's syndrome or other structural problems affecting the reproductive tract
  • People who currently smoke or drink more than 40g of alcohol per day
  • People who have a previous diagnosis of blood sugar problems, high blood pressure, abnormal cholesterol, heart or lung disease, kidney disease, liver disease, coeliac disease, any condition affecting nutrient absorption, chronic inflammatory disease, or cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Héctor F Escobar-Morreale, PhD, MD, Diabetes, Obesity and Human Reproduction Research Group (CIBERDEM), Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Phone: 34913369029

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Registry
ClinicalTrials.gov
Start date
31 January 2020
Est. completion
30 June 2025

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Adipokine and myokine signaling identification

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov